Take bone density, history of osteoporosis into consideration when prescribing.
Read More »What Do You Attribute The Change To?
56-year-old man, type 2 diabetes, had been prescribed SGLT-2 to lower his glucose levels. He had been taking an SGLT-2 for the past two years. His A1C, blood pressure and weight were elevated since the last visit 3 months ago. When asked if he was doing anything different, he said he had read articles and seen on TV about these types of medications causing heart disease, so he stopped taking his.
Read More »Europe Agrees: Learn the Signs of Atypical DKA in Patients Using SGLT-2s
European committee affirms benefits of SGLT-2s while urging healthcare providers to be vigilant and educate patients for signs and symptoms of atypical DKA.
Read More »Empagliflozin: Potential New Approach to Treating T2DM
Empagliflozin is proving to be a strong proponent for monotherapy in patients with T2DM.
Read More »Use of SGLT-2 Inhibitors Combo with Metformin for Greater Glycemic Control
Is there actual benefit in dual therapy treatment?
Read More »The Benefits of SGLT-2 and GLP-1s
In part 3 of this Exclusive Interview, Dr. Rhinehart shares his thoughts with DIC publisher Steve Freed on the benefits of SGLT-2 and GLP-1s. What do these new medications offer when it comes to costs, side effects and staying on top of the research to help facilitate use in the right patients?
Read More »Empagliflozin Potentially Protects Pancreatic Beta-cells in T1DM
New animal study shows the effects of empagliflozin, an SGLT-2 inhibitor, on the pancreatic cells of mice.
Read More »Diabetes for Cardiologists Part 9
In this week's Homerun Slides, surprising information about SGLT-2 inhibitors.
Read More »Shifting Paradigm in Diabetes Treatment – An Interview with Dr. Vinik
How SGLT-2 inhibitors can provide new approach over treatment centered on attaining glycemic control, intensive therapy.
Read More »Transcript: Dr. Aaron Vinik Discusses the Shift in Diabetes Care
In part 1 of this exclusive interview, DIC publisher Steve Freed talks with Dr. Aaron Vinik about the shift away from rigorous glycemic control in favor of greater focus on the impact of diabetes treatment on the heart.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.